Allegri RF

General

Full name :

First name :

Mail :

Zip Code :

City :

Country :

Email :

Phone :

Fax :

Website :

Directory :

References (3)

Title : The safety, tolerability, and efficacy of once-daily memantine (28 mg): a multinational, randomized, double-blind, placebo-controlled trial in patients with moderate-to-severe Alzheimer's disease taking cholinesterase inhibitors - Grossberg_2013_CNS.Drugs_27_469
Author(s) : Grossberg GT , Manes F , Allegri RF , Gutierrez-Robledo LM , Gloger S , Xie L , Jia XD , Pejovic V , Miller ML , Perhach JL , Graham SM
Ref : CNS Drugs , 27 :469 , 2013
Abstract : Grossberg_2013_CNS.Drugs_27_469
ESTHER : Grossberg_2013_CNS.Drugs_27_469
PubMedSearch : Grossberg_2013_CNS.Drugs_27_469
PubMedID: 23733403

Title : [Treatment of Alzheimer's Disease cognitive symptoms] - Abel_2008_Vertex_19 Suppl_39
Author(s) : Abel C , Allegri RF , Garau L , Genovese O , Mangone CA
Ref : Vertex , 19 Suppl :39 , 2008
Abstract : Abel_2008_Vertex_19 Suppl_39
ESTHER : Abel_2008_Vertex_19 Suppl_39
PubMedSearch : Abel_2008_Vertex_19 Suppl_39
PubMedID: 18392212

Title : [Mild cognitive impairment. Survey of attitudes of specialists and general physicians. mild] - Serrano_2007_Medicina.(B.Aires)_67_19
Author(s) : Serrano CM , Allegri RF , Caramelli P , Taragano FE , Camera L
Ref : Medicina (B Aires) , 67 :19 , 2007
Abstract : Serrano_2007_Medicina.(B.Aires)_67_19
ESTHER : Serrano_2007_Medicina.(B.Aires)_67_19
PubMedSearch : Serrano_2007_Medicina.(B.Aires)_67_19
PubMedID: 17408016